Summary & Overview
HCPCS J3473: Injection, Hyaluronidase Recombinant, 1 USP Unit
HCPCS Level II code J3473 designates recombinant hyaluronidase supplied and billed per 1 USP unit, an enzymatic injectable used to enhance dispersion and absorption of co-administered medications. Nationally, this code matters because it supports accurate billing for drug-facilitated administration techniques across ambulatory and outpatient settings, affecting reimbursement, clinical documentation, and inventory management for practices that administer subcutaneous or intramuscular therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for J3473, common sites of service where the product is used, and the payer landscape relevant to coverage and billing practice. The publication outlines typical billing considerations, benchmark framing, and recent policy focal points that influence how this injectable is documented and reimbursed at a national level.
The content provides practical reference material for revenue cycle and clinical staff: definitions of the code and service type, payer coverage scope, common modifier usage (listed separately), and pointers to areas where institutions commonly record associated diagnoses and related codes. Data not available in the input is noted explicitly where applicable.
Billing Code Overview
HCPCS Level II code J3473 represents an injectable medication: hyaluronidase, recombinant, billed per 1 USP unit. This product is an enzymatic agent used to increase tissue permeability and facilitate dispersion and absorption of other injected drugs or fluids.
-
Service type: Injectable medication administration (facilitator/enhancer for subcutaneous or intramuscular drug delivery)
-
Typical site of service: Ambulatory clinic, physician office, outpatient infusion center, or hospital outpatient department where injectable medications are administered
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an outpatient surgical center, dermatology clinic, ophthalmology clinic, or hospital perioperative unit requiring enzymatic dispersion of subcutaneous or intradermal hyaluronic acid-based fillers, walled-in or trapped local anesthetic, or to enhance dispersion of other injected medications. Common scenarios include post-filler nodules or lumps after cosmetic hyaluronic acid filler placement, facilitation of subcutaneous drug infiltration for chemotherapy extravasation, or to improve absorption of local anesthetic in regional blocks. The clinical workflow begins with evaluation and informed consent, documentation of the indication and prior filler type or extravasation event, preparation of recombinant hyaluronidase supplied in USP units, administration of the indicated number of units via subcutaneous or intradermal injections directly into or around the affected area, and post‑injection observation for allergic reaction or improvement. Typical sites of service are outpatient clinics, ambulatory surgery centers, emergency departments, and inpatient wards depending on indication and patient acuity. Clinician types commonly performing the injection include dermatology, plastic surgery, ophthalmology, emergency medicine, and anesthesiology teams, often accompanied by nursing staff for medication preparation and monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified | Not typically used; reserved if no other modifier applies per payer rules |